Vanda Pharmaceuticals (VNDA) Accumulated Depreciation & Amortization (2011 - 2025)

Vanda Pharmaceuticals' Accumulated Depreciation & Amortization history runs 15 years deep, the most recent figure standing at $12.6 million for Q4 2025.

• In Q4 2025, Accumulated Depreciation & Amortization rose 9.07% year-over-year to $12.6 million; the TTM figure through Dec 2025 stood at $12.6 million (up 9.07% YoY), while the FY2025 annual figure was $12.6 million, up 9.07% from the prior year.
• Accumulated Depreciation & Amortization came in at $12.6 million for Q4 2025 at Vanda Pharmaceuticals, up from $11.6 million in the prior quarter.
• In the past five years, Accumulated Depreciation & Amortization ranged from a high of $12.6 million in Q4 2025 to a low of $9.4 million in Q4 2021.
• A 5-year average of $11.0 million and a median of $11.2 million in 2023 frame the typical range for Accumulated Depreciation & Amortization.
• Across the five-year window, Accumulated Depreciation & Amortization grew 16.8% in 2021 and gained 3.45% in 2024, its largest moves.
• Vanda Pharmaceuticals' Accumulated Depreciation & Amortization stood at $9.4 million in 2021, then rose by 11.11% to $10.4 million in 2022, then rose by 7.31% to $11.2 million in 2023, then climbed by 3.45% to $11.6 million in 2024, then advanced by 9.07% to $12.6 million in 2025.
• According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods registered $12.6 million, $11.6 million, and $11.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison